MedTrace Logo

Treatment of Refractory (Acute or Chronic) Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell

NCT00447460 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2007-03-22

No results posted yet for this study

Summary

Clinical trial based on the use of a new therapeutic strategy (MSC infusion) for the treatment of patients who have developed a GVHD refractory to the usual therapeutic measures after undergoing an allogenic hematopoietic stem cell transplant.

Conditions

  • Graft-vs-Host Disease (GVHD)

Interventions

PROCEDURE

Mesenchymal stem cell (MSC)

Sponsors & Collaborators

  • Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán

    collaborator OTHER

  • University of Salamanca

    lead OTHER

Principal Investigators

  • Consuelo del Cañizo, MD · Haematology Service, University Hospital of Salamanca

  • José A Pérez-Simón, MD · Haematology Service, University Hospital of Salamanca

  • David Varcárcel Ferrerías, MD · Haematology Service, Santa Creu i Sant Pau Hospital, Barcelona

  • Carmen Martínez Muñoz, MD · Haematology Service, Clinic i Provincial Hospital, Barcelona

  • José Rifón Roca, MD · Haematology Service, University Clinic of Navarra

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Completion
2009-08-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00447460 on ClinicalTrials.gov